Joseph H. Zeidan, David M. Levi, Ruth Pierce, Mark W. Russo – 25 April 2018 – Liver transplantation (LT) is hospital‐resource intensive and associated with high rates of readmission. We have previously shown a reduction in 30‐day readmission rates by implementing a specifically designed protocol to increase access to outpatient care. The aim of this work is to determine if the strategies that reduce 30‐day readmission after LT were effective in also reducing 90‐day readmission rates and costs.

Alix P. M. Matton, Yvonne Vries, Robert J. Porte – 25 April 2018

Mark Thursz, Michael Allison – 25 April 2018

Damiano Patrono, Mauro Salizzoni, Renato Romagnoli – 25 April 2018

Donelle Cummings, Richard Ferstenberg – 25 April 2018

In this webinar, we will review the role of diet and exercise in the management of NAFLD. Specifically, we will overview the data in support of specific nutritional programs and physical activity regimens that have been shown to improve histologic components of NAFLD and NASH. Lastly, we will outline the remaining knowledge gaps and barriers related to lifestyle interventions in the treatment of NAFLD/NASH.Michelle Long Michelle T.

Jasmohan S. Bajaj, Richard Moreau, Patrick S Kamath, Hugo E. Vargas, Vicente Arroyo, K. Rajender Reddy, Gyongyi Szabo, Puneeta Tandon, Jody Olson, Constantine Karvellas, Thierry Gustot, Jennifer C. Lai, Florence Wong – 24 April 2018 – Acute on chronic liver failure (ACLF) is the culmination of chronic liver disease and extrahepatic organ failures, which is associated with a high short‐term mortality and immense health care expenditure. There are varying definitions for organ failures and ACLF in Europe, North America, and Asia.

Angela C. Cheung, Aliya F. Gulamhusein, Brian D. Juran, Erik M. Schlicht, Bryan M. McCauley, Mariza de Andrade, Elizabeth J. Atkinson, Konstantinos N. Lazaridis – 24 April 2018 – The United Kingdom‐Primary Biliary Cholangitis (UK‐PBC) risk scores are a set of prognostic models that estimate the risk of end‐stage liver disease in patients with PBC at 5‐, 10‐ and 15‐year intervals. They have not been externally validated outside the United Kingdom.

Jasmohan S. Bajaj, Richard Moreau, Patrick S Kamath, Hugo E. Vargas, Vicente Arroyo, K. Rajender Reddy, Gyongyi Szabo, Puneeta Tandon, Jody Olson, Constantine Karvellas, Thierry Gustot, Jennifer C. Lai, Florence Wong – 24 April 2018 – Acute on chronic liver failure (ACLF) is the culmination of chronic liver disease and extrahepatic organ failures, which is associated with a high short‐term mortality and immense health care expenditure. There are varying definitions for organ failures and ACLF in Europe, North America, and Asia.

Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B. Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth‐Miller, Vedran Pavlovic, Cynthia Wat – 24 April 2018 – Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG‐B‐ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa‐2a treatment in children aged 3 to <18 years with CHB.